Coxibs are a major advance in the therapy of @entity1 with @entity158 and inflammatory conditions. At present, the theoretical harm that derives from inhibiting vascular @entity2247 has not emerged as a significant risk, although more research is needed. What has emerged is that some NSAIDs, particularly naproxen, may have an @entity117 -like effect in reducing the risk of @entity455 , although more research is needed. Whether this finding is sufficient to recommend naproxen for the management of @entity1 with @entity625 who also require vascular protection is intriguing and worth further evaluation. It is widely believed and maintained that coxibs have the greatest potential value in @entity1 with other risk factors for @entity1066 , and this seems likely to be the case for @entity1 taking corticosteroids or anticoagulants and probably those who are elderly. Dosing should be [figure: see text] cautious in old @entity1 , however, because of the ability of NSAIDs and coxibs to cause fluid retention, @entity712 , and @entity101 . It is less clear that coxibs reduce risk sufficiently in @entity1 with previous @entity1066 (particularly recent) to make them a better strategy than acid co-therapy. This possibility requires further evaluation, as does the competing value of the 2 strategies for @entity1 infected with @entity1534 . If coxibs are used in @entity1 with @entity1534 -associated risks, there are grounds to recommend eradication. For @entity1 taking @entity117 or drugs [figure: see text] with an @entity117 -like effect, the intrinsic risk of these drugs may mandate use of acid suppression and obviate the use of coxibs (Fig. 8). Available data suggest that the risk reduction in @entity1 with no risk factors who use coxibs may be almost as great as in @entity1 with risk factors, with the added advantage that @entity1 may be taken to a state that is virtually free of any risk of @entity1066 complications that otherwise might require additional therapy. Contrary to current popular truisms, the greatest value of coxibs may be in @entity1 without risk factors because it is in this unconfounded group that the ability of coxibs to free @entity1 of @entity1066 risk appears to be delivered in full.

Gastrointestinal safety of XXXX specific inhibitors.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disease'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer', 'ulcer disease', 'ulceration'] @entity158 :: ('MESH:D010146', 'Disease') :: ['painful'] @entity1534 :: ('210', 'Species') :: ['H. pylori'] @entity2247 :: ('4513', 'Gene') :: ['COX-2']
@entity2247 :: (4513,Gene) :: ['COX-2']
